Highest-materiality recent filing
BioAtla faces Nasdaq delisting; trading to suspend Aug 31
Nasdaq Listing Council affirmed delisting on Aug 26, 2026; suspension at open Aug 31, 2026.
BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M
Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.
BioAtla shareholders approve 1-for-50 reverse stock split merger; executive retention bonuses set
Stockholders approved Merger and Share Consolidation (1:50 reverse split) on March 23, 2026; 49.2M votes for, 1.47M against.
BioAtla initiates strategic review, cuts 70% workforce; CFO replaced; cash ~$7.1M
Workforce reduced ~70%; severance costs estimated $0.5-0.6M; committed Feb 24, 2026.
Nasdaq Listing Council stays BCAB delisting, calls review of Feb 6 non-compliance determination
Nasdaq determined Feb 6 to delist BCAB for non-compliance with bid price ($1) and stockholders' equity ($2.5M) requirements.
BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10
Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk
Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.
BioAtla issues super-voting share to CEO; reverse stock split vote fails, adjourned to Jan 26
Issued one share of Series A Junior Preferred Stock to CEO Jay Short for $0.01, granting vote power equal to outstanding common shares on reverse split proposals.
BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership
Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.
BioAtla special meeting adjourned; reverse stock split proposal lacks sufficient votes
Proposal 1 (issuance of common stock under pre-paid advance agreements) passed: 19.8M for, 9.4M against.
BioAtla raises $7.5M via PPAs and $15M SEPA; Yorkville gets 243,428 commitment shares
PPAs for $7.5M face amount; net proceeds ~$7.13M at 95% of face; due in 12 months.
BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end
Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.
BioAtla granted Nasdaq continued listing with conditions through Feb 2026
Nasdaq Panel approved continued listing pending transfer to Capital Market by Sept 26, 2025 (filed Sept 18).
BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC
Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.
BioAtla receives Nasdaq delisting notice for failing $10M equity requirement
Stockholders' equity was $547K as of March 31, 2025, far below the $10M minimum for Nasdaq Global Market.
BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC
Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.
BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts
Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
BioAtla receives Nasdaq notice of non-compliance with minimum bid price rule; 180 days to cure
Received Nasdaq notice on Feb 6, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days.
BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs
Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.
BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026
Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.
BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M
BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.
BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin
Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.
Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.
BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024
Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.
Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.
BioAtla Q3 net loss $33.3M; FDA backs registrational path for BA3011 in NSCLC
Net loss widened to $33.3M in Q3 2023 from $25.8M a year ago, driven by a 43% rise in R&D costs.
BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025
Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.
BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials
Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.
BioAtla enters underwriting agreement to sell 9.745M shares at $6.67/share for $65M gross proceeds
Offering of 9,745,128 common shares at $6.67 each; gross proceeds $65M before discounts and expenses.
BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011
NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.
BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy
Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.
On February 15, 2024, the Compensation Committee approved the promotion of Christian Vasquez from SVP of Finance to Chief Accounting Officer.
On February 24, 2023, Scott Smith, President of BioAtla, Inc. (“BioAtla”) notified BioAtla of his intention to resign, effective February 27, 2023, in order to pursue a new opportunity as Chief Executive Officer at Viatris Inc.
On February 9, 2023, the Compensation Committee approved the promotion of Christian Vasquez from VP of Finance to SVP of Finance.
On June 3, 2022, Guy Levy informed BioAtla, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective June 16, 2022, the date of the Company’s 2022 Annual Meeting of Shareholders.
On December 16, 2021, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Edward L. (Eddie) Williams to the Board, effective December 16, 2021.
Max materiality 0.90 · Median 0.62 · Most common event other_material